Matrix Metalloproteinase 2: an important genetic marker for cholesteatomas by Morales, Douglas Salmazo Rocha et al.
51
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 73 (1) JANUARY/FEBRUARY 2007
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
Matrix Metalloproteinase 2: an 
important genetic marker for 
cholesteatomas.
   Summary
Douglas Salmazo Rocha Morales 1, Norma de 
Oliveira Penido 2, Ismael Dale Coltrin Guerreiro 
da Silva 3, João Norberto Stávale 4, Arnaldo 
Guilherme 5, Yotaka Fukuda 6
1 PhD and M.S. Assistant Physician – University Hospital - USP. 
2 PhD and M.S. Assistant, Head of the Interdisciplinary Otology Department of ENT/HNS - EPM Unifesp. 
3 PhD. Associate Professor – Department of Molecular Gynecology - EPM Unifesp. 
4 PhD and M.S. Assistant Professor – Department of Pathology - EPM Unifesp. 
5 PhD and M.S. Professor – Department of Otorhinolaryngology - EPM Unifesp. 
6 PhD and M.S. Associate Professor – Department of ENT/HNS EPM Unifesp e do Hospital do Servidor Público Estadual de São Paulo. 
E-mail: douglas.morales@uol.com.br 
Paper submitted to the ABORL-CCF SGP (Management Publications System) on December 22th, 2005 and accepted for publication on January 4th, 2006. cod. 1660
Aim: This study is to determine the MMP2’s presence in 
cholesteatomas and whether complicating cholesteatomas 
show a higher immunohistochemical expression of matrix 
metalloproteinase 2. Cholesteatoma produces enzymesthat 
cause bone erosion like Matrixmetalloproteinase 2 (MMP2). 
Material and Methods: We analyzed the expression 
of MMP2 in invasive (causing complications) compared 
to latent cholesteatomas (not causing complications). A 
crosssectional study with nineteen slides and paraffin 
blocks of cholesteatomas derived from mastoidectomies 
were located and processed, including 8 invasive and 11 
latent cholesteatomas. Immunohistochemical thecnique was 
empregated to MMP2. Results: The results are expressed as 
0, + (to low), ++ and +++(high) according to the quantity 
and color of the immunohistochemical staining of MMP2. 
Higher expression of MMP2 was observed in 7 (87.5%) 
of the 8 invasive cholesteatomas. With respect to latent 
cholesteatomas, higher expression of MMP2 was observed in 
27.3% (3 cases), with Fisher’s exact test indicating a significant 
difference (p=0.015). Conclusions: Cholesteatoamas 
express MMP2 and Invasive cholesteatomas had high MMP2 
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INTRODUCTION
A daily cholesteatoma approach is part of most 
otorhinolaryngologists’ routine. Notwithstanding, we still 
lack a genetic marker that predicts its complication poten-
tial. The marker hereby chosen is called Matrix Metallopro-
teinase 2 (MMP2). Metalloproteinases are enzymes capable 
of causing bone erosion, especially the MMP2, which has 
become object of correlation with cholesteatomas. Based 
on samples of more and less aggressive cholesteatomas 
(given clinical signs and the complications brought about 
by the disease), except for congenital cholesteatomas and 
patients with acquired cholesteatomas in less than 14 years 
(average time length taken by the cholesteatoma in order 
to bring about complications), we tried to show whether 
or not there is a correlation between the expression of 
type 2 metalloproteinase (MMP2) and the cholesteatoma’s 
aggressiveness.
Our goal with the present investigation is to observe 
if cholesteatomas in general produce matrix metallopro-
teinase 2 (MMP2), and if more aggressive cholesteatomas 
produce a higher quantity of MMP2.
Cholesteatoma and complications
According to Ribeiro Pereira1, a cholesteatoma is an 
epidermal cyst, made up of keratinized epidermal tissue, 
capable of migrating and eroding adjacent structures, fre-
quently found in temporal bones with history of chronic 
otitis media. The epidermoid cyst bears an external matrix 
formed by stratified keratinized squamous epithelium over 
a secondary matrix of fibro-connective tissue (connective 
tissue bearing collagen elastic fibers, a mash of fibers, 
fibroblasts, lymphocytes, histiocytes and plasmocytes). 
From the histological stand point, the epithelium is simi-
lar to the epidermis, and its four basic layers can be seen 
(basal, squamous, granulous and cornea). Such matrix 
sheds keratin lamellae to within the space limited by 
the epidermal sac, filling and distending it. According to 
Soldati and Mudry2 the cholesteatoma was first described 
in 1829, by Curvalhier, as a tumor-like process, and was 
thus called because of the cholesterol found inside, as it 
was also described by Muller in 1830. There is a report 
that in 1683, Duverney described a temporal bone tumor 
that may very well have been a cholesteatoma. In 1855, 
Virchow thought the cholesteatoma was a tumor that in-
creased in size because of mesenchymal cell metaplasia 
towards epithelial ones. Gruber, Wendt and von Troelsch, 
in 1868, described the cholesteatoma as the result of tym-
panic membrane cell metaplasia into malpighia epithelium. 
In 1869, Politzer stated that the cholesteatoma was but a 
glandular neoplasia of the middle ear mucosa. Bezold and 
Habermann, in 1889, published that the cholesteatoma 
was the result of an epidermal migration from the external 
auditory canal towards the middle ear cavity via a margi-
nal perforation after an episode of chronic or acute otitis 
media. In 1980, Plester3 stated that hereditary or genetic 
factors influenced the degree of mastoid pneumatization, 
by skull base alterations that interfered in the Eustachian 
tube anatomical position and patency, thus altering mas-
toid pneumatization. In cholesteatoma patients, the angle 
formed by the posterior glenoid process and the posterior 
border of the hard palate is significantly smaller when com-
pared to patients without cholesteatoma. The epipharynx 
configuration is considerably smaller in cholesteatoma 
patients. Albino, Kimmelman and Parasier4 analyzed stu-
dies about the cholesteatoma ultrastructure and concluded 
that: (1) cholesteatomas do not present inherent genetic 
instability, differently from malignant neoplasias; (2) The 
induction of hyperproliferative cells in the cholesteatoma 
epidermal base implies an idiopathic response poten-
tial, originated from internal events and external stimuli, 
through cytokines produced by inflammatory cells. (3) 
Bacteria may initiate the cholesteatomatous process. (4) So 
far, there are no molecular or cellular differences among 
the different cholesteatoma types (primary, secondary, 
recurrent, congenital). According to Caldas and Caldas 
Neto5, the expansive and destructive capacity inherent to 
cholesteatomas may compromise the middle ear ossicular 
chain, eventually bringing about erosions to the inner ear 
bony protection, facial nerve, meninges and lateral sinus, 
causing irreversible lesions and remote infections that may 
leave patients with permanent functional disabilities or 
even death. According to Morales, Cervantes and Testa6, 
who in 2001 described the possibility of cholesteatomas 
producing intra and extracranial complications (neck and 
face) because of erosions caused to the adjacent tem-
poral bone and the secondary infection induced by this 
very erosion. Extracranial complications are: labyrinthitis, 
deafness, peripheral facial paralysis, mastoiditis (Bezold 
type, squamous-zygomatic and Mouret type) and middle 
ear ossicular chain destruction (malleus, incus and stapes). 
Intracranial complications are: meningitis, meningoen-
cephalitis, cerebral or cerebellar empyema, cerebral or 
cerebellar abscess and lateral sinus thrombosis. Voegels, 
Garcia, Bogar, Miniti and Bento7 studied 14 patients with 
cholesteatoma-induced semicircular canal fistula, with 
anacusis as a major disease complication. In 2001, Penido 
and Fukuda8 studied 25 cases of brain abscess (cerebral 
or cerebellar) of otological origin and concluded that most 
of the times the cause is a cholesteatomatous chronic otitis 
media, and besides draining the encephalic abscess, the 
mastoid should be opened in order to clear the infectious 
process. In 2003, Cruz, Kasse and Leonhart9 presented a 
retrospective study that revised 84 (eighty-four) ears with 
chronic otitis media, 41 (forty-one) non-cholesteatomatous 
and 43 (forty-three) cholesteatomatous, and observed that 
canal wall down mastoidectomy precludes disease recur-
rence (4%); while the canal wall up procedure yielded 
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a 10% recurrence rate. In 2003, Testa, Vicente, Abreu, 
Benbassat, Antunes and Barros10, carried out a retros-
pective study involving 206 facial nerve decompressions 
in order to treat peripheral facial paralysis and observed 
10 cases (4.85%) of cholesteatomas as the cause for such 
complication. In 2005, Penido, Borin, Iha, Suguri, Onishi, 
Fukuda and Cruz11, in a retrospective study that analyzed 
therapeutic options in 33 (thirty-three) patients with oti-
tis media causing intracranial complications, found the 
cholesteatoma to be the most common etiology of such 
complications (26 cases, or 79%).
Cholesteatomas and the Matrix Metalloproteinase 2
In 1996, Schonermark, Mester, Kempf, Blaser, 
Tscheche and Lenarz12 found that tissue invasion by 
cholesteatomas is related to the MMP2, which had also 
been described in 1996, by Gohlke, GomisRuth, Crabbe, 
Murphy, Docherty and Bode13, then called Gelatinase A, 
that bears a non-catalytic C terminal domain that bears 
a homologous sequence and haemopexin. Deslogue et 
al.14 (1997), in a study called: Human cholesteatoma 
DNA analysis, noticed the presence of euploid DNA in 
cholesteatomas. Banerjee, James and Narula15 (1997) by 
means of the Western blotting technique, showed the pre-
sence of metalloproteinase 2 (MMP2) in cholesteatomas. 
Metalloproteinase 2 (MMP2) or Gelatinase A or 72 Kda 
collagenase is a protein induced in the cell nucleus and 
is related to properties such as tumor progression - inclu-
ding growth, invasion, metastasis and angiogenesis (blood 
vessel growth), agreeing with Sun and Hemler16 (2001), 
who recognized the extracellular interactions of the MMP2, 
acting as proteolytic enzymes capable of degrading tissue 
connective components. Zhu, Xie and Wang17 (2001), in 
a study called “Matrix  metalloproteinase 2,9 expression 
in middle ear cholesteatoma and cancer”, by means of 
immunehistochemical methods for MMP 2 and 9, used 36 
cholesteatomas and 10 external ear skin fragments and 
16 middle ear cancer fragments, observed a direct rela-
tion between cholesteatomas and MMP2 and MMP9, thus 
concluding that this disorder between metalloproteinases 
and their inhibitors was one of the reasons for bone re-
sorption in middle ear cancer and cholesteatoma cases. 
Bernal Sprekelsen, Ebmeyer, Anonopoulos, Borkowiski 
and Sudhoff18 (2001) stated in their study called: “Middle 
ear cholesteatoma base membrane alterations “, that the 
cholesteatoma epithelium is characterized by the lack of 
keratinocyte regulation, followed by the destruction of 
ossicles and other temporal bone parts. By means of im-
munohistochemistry, they noticed that metalloproteinases 
and the basic fibroblast growth factor may explain both 
destructive and proliferative middle ear cholesteatoma ac-
tivities. In an experimental study with gerbils (Mongolian 
squirrel) (published in 2002), they tested the MMP2 topical 
inhibitor, Ilomostat, observing whether or not there is any 
relation with the formation of atelectasis on the tympanic 
membrane of these animals, and no statistical difference 
was observed between the group that received the drug for 
eight weeks (6 animals) and the control group (7 animals); 
it could not be stated for sure that the same thing could 
correlate to human cholesteatomas. In 2003, Wilmoth, 
Schultz and Antonelli19 studied 48 gerbils and observed 
that metalloproteinases are Zinc (Zn)-linked enzymes, and 
represent elements capable of destroying the extracellular 
matrix. According to the authors, MMPs are known for 
participating in normal collagen metabolism physiology, 
but are also associated to pathological absorptions, partici-
pating in chronic inflammatory skin processes, tumors and 
metastasis in the extracellular matrix. MMP’s activities are 
regulated by metalloproteinase inhibitors and the breakage 
of such harmony may trigger a pathological process. In 
this study, the tympanic membranes of the animals were 
placed within cultures with bacterial toxins (lipopoly-
saccharides and alpha tumoral necrosis factor), noticing 
that their chains started to Express a greater amount of 
metalloproteinases (MMP2), which could contribute to the 
bone resorption process. 
In a study published in 2004, Gaiotto et al.20 descri-
bed that metalloproteinase 2 (MMP2) expression in normal 
uterine cervix, intraepithelial neoplasia and uterine cervix 
squamous cell carcinoma was gradually higher according 
to the degree of malignity and infiltration. The study sho-
ws that MMP2 is an enzime produced in the cell nucleus 
and its expression is related to its capacity to infiltrate 
and invade adjacent tissue. While that paper was being 
published, the concept of MMP2 tissue invasion was used 
in relation to cholesteatomas in this study.
METHODS
This research project has been submitted to the 
Ethics in Research Committee of the Federal University 
of São Paulo - São Paulo Hospital, and approved under 
protocol # 0322/03. Mastoidectomies were carried out 
in the São Paulo University Hospital-Federal University 
of São Paulo in the last 10 years, due to middle ear cho-
lesteatomas. We investigated patients’ charts, looking for 
cholesteatoma-related complications (mastoiditis, labyrin-
thitis, peripheral facial paralysis, encephalitis, meningitis, 
lateral sinus thrombophlebitis, cerebral abscess, cerebellar 
abscess), as an indication of worse prognosis (more ag-
gressive). Patients below 14 years of age and those with 
congenital cholesteatomas were taken off the sample, thus 
reducing sample size, together with technical difficulties 
related to the storage of paraffin blocks, slide labeling and 
immunohistochemical reactions. Treatment is primarily sur-
gical, in other words, mastoidectomy, according to a study 
published by Cruz, Kasse and Leonhart, when fragments 
are removed for pathology and immunohistochemical 
analysis. We used 19 cholesteatoma paraffin blocks (8 of 
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the aggressive type). We then proceeded with the immuno-
histochemical analysis in order to detect MMP2 expression. 
The paraffin blocks were cut in slides measuring from 3 to 
4 micrometers, and assembled in previously labeled slides 
at 4%. The paraffin was then removed from the slides using 
an oven at 57ºC during the night, and they were immersed 
in a xylol bath in the following duration sequence: 30, 5 
and 5 minutes more. They were then hydrated in ethylic 
alcohol in decreasing concentrations of 100%, 80% and 
70%, respectively; each one lasting 5 minutes, and were 
then washed in tap water. 
On the following step, we carried out antigenic 
recovery in a microwave oven (maximum power output 
of 700 Watts), and the slides were placed in a sodium ci-
trate buffer solution, pH=6.0, during 45 minutes, and were 
then washed in tap water. Endogenous peroxidase block 
was carried out with four 5 minute baths in 20 volumes 
hydrogen peroxide (H2O2), followed by distilled water 
wash and PBS (saline solution buffered with phosphates), 
pH= 7.4 7.6. We used antibody MMP2/72kDa Collagenase 
IV (Human, Mouse, Rat and Cow) Paraffin diluted in BSA 
1% (bovine albumin serum) at 1: 150 titration. All the slides 
were then placed in a single chamber at 4ºC for the night. 
The material was washed with PBS buffer and incubated 
with the biotinilated secondary antibody. Washed with 
PBS solution. 
In order to develop the reaction we used a chromo-
genic substrate, the DAB solution (33-Diaminobenzidine) 
at the rate of 0.06g for 100 ml of PBS and 1 ml of H2O2 
at 20 volumes, for 5 minutes at 37ºC. As a final product of 
such reaction, we observed in the microscope the shape 
of a dark brownish precipitate. The material was then 
washed in tap water and counter-dyed with “Hematoxylin 
Mayer” for 3 minutes. Following, it was submitted to 3 
baths of xylol for diafinizing. The slides were then, finally, 
assembled with micro slides and Entellan®.
Slide reading was carried out under light micros-
copy with a 200 and 400 times magnification (Olympus 
BX 40 microscope), by two independent observers (one 
of them is a professor of pathology and the other is the 
researcher himself). We observed whether or not MMP2 
was present in the cholesteatoma samples and the inten-
sity of MMP2 coloring. The result was expressed in 0, +, 
++ and +++, according to the amount of MMP2 and color 
intensity found (attenuated or absent, beige, brown, dark 
brown, respectively).
RESULTS
The 19 cholesteatoma slides (8 of them were inva-
sive) underwent an immunohistochemical technique for 
MMP2 detection, causing the reading of a qualitative MMP2 
presence in the outer portion of the cholesteatoma. The 
reading of the MMP2 immunohistochemical expression 
in the cholesteatoma slides was expressed in values of: 0 
(Attenuated), + (Mild), ++ (Moderate) and +++ (Intense). 
(Figure 1).
We can see that in the nineteen cases analyzed, 
fifteen presented mild, intense or moderate MMP2 expres-
sion, making up a total of 78.9% of the initial sample and 
the remaining were attenuated, though present. Of the 
cholesteatomas that did not present clinical complications, 
eleven of the nineteen studied, two of them expressed 
attenuated MMP2 (18.1%), six expressed MMP2 with mild 
intensity (54.6%), three expressed MMP2 with moderate 
intensity (27.3%). Of the cholesteatomas that presented 
complications, eight of the nineteen: one had attenuated 
MMP2 expression (12.5%), three expressed MMP2 mode-
rately (37.5%), and four strongly expressed MMP2 (50%). 
(Chart 1, Table 1 and Graph1).
DISCUSSION
It is conceptually accepted that each and every 
cholesteatoma bears the potential to cause intra and extra-
cranial complications, as stated by Penido et al. (in 2004) 
in a retrospective study that analyzed therapeutic options 
for cholesteatoma treatment in 33 patients with intracra-
nial complications caused by otitis media, observing that 
the cholesteatoma is the most common basic etiology 
of these complications (26 cases or 79%) ; Caldas and 
Caldas Neto in 1988; and Morales, Cervantes and Testa in 
2001, described the intracranial (meningitis, encephalitis, 
cerebral abscess, cerebellar abscess and empyema) and 
extracranial (neck and face: peripheral facial paralysis, 
labyrinthitis, mastoiditis: Bezold, Mouret, squamous-zygo-
matic and cervical abscesses) complications. According 
to Plester (1980), hereditary or genetic factors influence 
the degree of mastoid pneumatization, causing narrower 
angles at the attic, a determining factor for the generation 
of more aggressive cholesteatomas; this by itself seems 
to be enough to explain precisely the erosion caused by 
cholesteatomas to the adjacent bone tissue in some cases 
and not in others, suggesting that there must be some in-
trinsic cholesteatoma expression factor that would explain 
why the erosion caused by some cholesteatomas is greater 
(and thus brings complications) than by others.
Thus, from an universe of studies about collagena-
ses, growth inhibitors and cholesteatoma prolipheration, 
osteolytic enzymes, bacterial toxins such as lipopolysac-
charides and tumor necrosis alpha factor, in 1996, Schoner-
mark, Mester, Kempf, Blaser, Tscheche and Lenarz studied 
cholesteatomas and metalloproteinases, which are prote-
olytic enzymes responsible for bone homeostasis, present 
in greater quantities in osteolytic inflammatory diseases 
and observed the presence of MMP2, MMP9 and MMP3 
in the basal and suprabasal cells of cholesteatomas. The 
results of this study indicate the possibility that members 
of the metalloproteinase family may activate bone invasion 
mechanisms in cholesteatomas.
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Back in 1998, Banerjee, James and Narula demons-
trated that MMP2 and MMP9 were present in cholesteato-
mas and in the external auditory canal skin. Apparently, 
such fact would hamper research, since the normal external 
auditory canal tissue also had the enzime deemed impor-
tant in the explanation of the bone erosion mechanism.
In 2001, Bernal Sprekelsen, Ebmeyer, Anonopou-
los, Bordowiski and Sudhoff, insisted and noticed that 
metalloproteinases and the fibroblast basic growth factor 
could explain cholesteatomas’ destructive and proliferative 
activities. 
Also in 2001, Zhu, Xie and Wang, published a study 
involving cholesteatomas and middle ear cancer, stating 
that the disorder between metalloproteinases and their 
inhibitors was one of the reasons behind middle ear cho-
lesteatoma and cancer causing bone resorption. Therefore, 
Figure 1. Picture of cholesteatoma slides submitted to MMP2 immu-
nohistochemistry reaction, presenting different intensities, read under 
light microscopy, with 200 and 400x magnifications. - attenuated and 
+/3+: Less MMP2 expression. ++/3+ and +++/3+: Greater MMP2 
expression.
Table 1. Shows the number of cholesteatoma slides, associating 
the complicated and non-complicated ones to gender, age, MMP2 
immunohistochemical expression, with the corresponding rate of 




Males 5 (45,5%) 4 (50%)
Age (years) 32,9 +-18,7 26,9 +-7,7
26,0 (17 - 50)




0 ou + 8 (72,7%) 1 (12,5%) # 0,015
++ ou +++ 3 (27,3%) 7 (87,5%)
# statistical test of significant Fisher.
Graph 1. Association between cholesteatomas (invasive and latent) 
and MMP2 immunohistochemical expression (greater and lesser). 
- MMP2: matrix metalloproteinase 2. Greater: greater (+++ and ++) 
MMP2 expression in the cholesteatoma. Lesser: lesser (attenuated and 
+) MMP2 expression in the cholesteatoma.
the assumption that MMP2 was expressed in cholesteato-
mas and the external auditory canal skin still had its wor-
th; that fact that they were raising is that cholesteatomas 
stimulated by infectious factors produce more MMP2 than 
the external auditory canal skin, which was then proved 
by Wilmoth, Schultz and Antonelli, in 2003, who observed 
in an experimental study that tympanic membranes of lab 
animals (gerbils) placed in a culture with bacteria toxins 
(lipopolysaccharides and tumor necrosis alpha factor), 
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expressed greater quantities of metalloproteinases. From 
this moment on, a question arised: what comes first, the 
infection or the metalloproteinase? Answer: the metallopro-
teinase, since it is embedded in the cell genetic code. But 
then, why not all cholesteatomas cause bone erosion? Why 
only some complicate? Because the expression is related 
to a mismatch between MMP activators and inhibitors; 
thus, some cells have a genotype with a greater capacity 
to express MMP2 when compared to others, bearing in 
mind that infection is a potent stimulus for metalloprotei-
nase expression by the cholesteatomatous cell. However, 
does a cholesteatoma complicate when it expresses more 
metalloproteinase or is it due to the fact that it harbors a 
more virulent infection (intense)? It is, in fact, a hard ques-
tion to answer. Nonetheless, if cholesteatomas produce 
more metalloproteinase, it will ultimately destroy more 
bone tissue, thus bringing forth complications.
In Chart 1, of the 11 patients with latent cholestea-
tomas, 2 had no MMP2 expression (0), six patients (6) had 
MMP2 expression of +, and 3 patients expressed MMP2 as 
++. In Chart 1, we may also notice that of eight (8) patients 
with invasive cholesteatomas, only one (1) had a lesser 
MMP2 expression (0); the remaining patients with invasive 
cholesteatomas manifested a higher MMP2 expression (++ 
and +++). (Figure 1).
These figures were statistically analyzed by the Fi-
Chart 1. Cholesteatoma slides and their association with patient’s gender, age, slide number, MMP2 expression intensity and complication (when 
it happened). - MMP2: matrix metalloproteinase 2.
Initials Gender Age Slide MMP2 reading Complication
D.G.P.V. Male 17 years B02 14933 ++ Lateral sinus thrombosis
R.M.D.S.S. Male 18 years B00 07723 ++ Left temporal lobe abscess
J.C.D.S. Male 24 years B02 28657 ++ Meningitis
O.C.D.S. Male 37 years B98 09318 +++ Left temporal bone abscess and meningitis
J.P.D.S. Female 22 years B01 18345 +++ Sigmoid sinus thrombosis and meningitis
A.P.D.S. Female 30 years B02 35536 +++ Sigmoid sinus thrombosis
A. . A . S. Female 35 years B03 32668 +++ Labyrinthitis and erosion of the facial nerve canal
V.L.B.D.S Female 32 years B04 04518 0 Meningitis and peripheral facial paralysis
W.F.P. Male 16 years B03 5856 0 No complications  
J.D.R. Male 17 years B92 408 ++ No complications  
R.P. Male 19 years B03 2724 0 No complications  
S.S.L. Male 66 years B03 24412 + No complications  
R.D.J.S. Male 21 years B03 4079 + No complications  
L.C.S. Female 15 years B03-521 ++ No complications  
E.N.D. Female 26 years B03 01011 + No complications  
S.H.V. Female 32 years B04 4205 ++ No complications  
L.G.G. Female 50 years B94 7353 + No complications  
S.M.S.B. Female 38 years B03 670 + No complications  
M.M.C.D.S. Female 62 years B03-1132 + No complications  
sher Exact Test, presenting significant results with p= 0.015, 
in other words, cholesteatomas that do complicate present 
a “++ or +++” immunohistochemical MMP2 expression, 
when compared to latent cholesteatomas that bear MMP2 
immunohistochemical expression of “0 or +”.
With the use of metalloproteinase inhibitors (ilomos-
tat), as mentioned in the experimental study carried out by 
Lehman, Wilmoth, Prevatt, Schultz and Antonelli (2002), 
and that of Wilmoth, Schultz and Antonelli (2003), it is 
suggested that cholesteatomas would cause less erosion to 
the adjacent bone tissue, and this may help prevent intra 
or extracranial complications (neck and face).
Another assumption we may suggest is that when 
we operate on a patient with cholesteatoma, if we carry 
out an MMP2 immunohistochemical reaction, we may 
increase the prognostic accuracy on the operated lesion. 
A greater challenge would be to study other enzymes 
from the family of metalloproteinases, in order to better 
understand the genetic content of a cholesteatoma, and 
thus be able to individualize its genetic characteristics for 
a given patient, and thus have a more accurate prognosis 
on its proliferation and erosive capacity. 
CONCLUSION
This study allows us to state that:
1.All cholesteatomas express MMP2, but 84% of the 
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cholesteatomas investigated express MMP2 lightly, mode-
rately and intensely; and 16% express attenuated MMP2 
(this is similar to what happens to other tissues).
2.Cholesteatomas that cause complications have 
a MMP2 immunohistochemical expression that is more 
intense, proven by the Fisher Exact Test, with p=0.015 
(significant), when compared to cholesteatomas that do 
not cause complications
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